15.5  0.78 (5.3%)		04-26 16:00
Open: 14.93 High: 15.5 Volume: 113,376		Pre. Close: 14.72 Low: 14 Market Cap: 684(M)

Short term
Mid term
Targets	6-month :	19.3	1-year :	21.49
Resists	First :	16.52	Second :	18.39
Pivot price	15.4
Supports	First :	13.48	Second :	11.22
MAs	MA(5) :	15	MA(20) :	15.71
	MA(100) :	12.13	MA(250) :	11.42
MACD	MACD :	-0.3	Signal :	-0.2
%K %D	K(14,3) :	44.7	D(3) :	41.7
RSI	RSI(14): 49.1
52-week	High :	47.16	Low :	6.69

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ ENGN ] has closed below upper band by 46.2%. Bollinger Bands are 45.5% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 1 bars. This is a sign that the market may be about to initiate a new trend.

If tomorrow:	Open lower	Open higher
High:	15.52 - 15.61	15.61 - 15.69
Low:	13.79 - 13.89	13.89 - 13.99
Close:	15.33 - 15.5	15.5 - 15.65

enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.

Tue, 23 Apr 2024
enGene Holdings Inc. (NASDAQ:ENGN) Major Shareholder Sells 4,575 Shares - MarketBeat

Tue, 12 Mar 2024
enGene Reports First Quarter 2024 Financial Results and Recent Corporate Progress - BioSpace

Wed, 14 Feb 2024
enGene Holdings Announces Private Placement and CEO Transition - TipRanks.com - TipRanks

Wed, 14 Feb 2024
Crude Oil Moves Lower; Louisiana-Pacific Posts Upbeat Earnings - Louisiana-Pacific (NYSE:LPX) - Benzinga

Wed, 14 Feb 2024
Dow Edges Higher; QuidelOrtho Shares Plummet | Markets Insider - Markets Insider

Wed, 14 Feb 2024
enGene's stock skyrockets as Montreal gene therapy developer raises $200-million on Nasdaq - The Globe and Mail

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Outperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Neutral
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Outperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	44 (M)
Shares Float	17 (M)
Held by Insiders	13.3 (%)
Held by Institutions	56.2 (%)
Shares Short	13 (K)
Shares Short P.Month	48 (K)

EPS	0
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	0
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	0 %
Return on Equity (ttm)	0 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	-0.73
Qtrly Earnings Growth	0 %
Operating Cash Flow	-26 (M)
Levered Free Cash Flow	0 (M)

PE Ratio	0
PEG Ratio	0
Price to Book value	0
Price to Sales	0
Price to Cash Flow	-26.41

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.